What is Schrödinger?
Computational chemistry software and drug discovery company with $256M 2025 total revenue; $200M 2025 software revenue scale.
- Category
- Computational chemistry software and drug discovery
- Headquarters
- New York, NY
- Founded
- 1990
- Employees
- 850+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: SDGR
What is Schrödinger?
Schrödinger is a Computational chemistry software and drug discovery company headquartered in New York, NY. As of June 2026, its clearest scale signal is $256M 2025 total revenue; $200M 2025 software revenue.
Schrödinger operates a physics-based computational platform for molecular discovery, paired with collaborative and proprietary drug-discovery programs. Its core customer set includes biopharmaceutical companies, academic labs, materials-science teams, drug-discovery groups, and internal therapeutic programs, and its public product surface includes Maestro, LiveDesign, FEP+, Glide, WaterMap. The current scale signal is $256M 2025 total revenue; $200M 2025 software revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Schrödinger offer?
Schrödinger offers Maestro, LiveDesign, FEP+, Glide and related healthcare workflows.
- Maestro· Core product
- LiveDesign· Core product
- FEP+· Core product
- Glide· Workflow
- WaterMap· Workflow
- Materials Science Suite· Workflow
- Hosted software· Platform
- Drug discovery collaborations· Platform
- Internal pipeline· Platform
How does Schrödinger make money?
Schrödinger earns software subscription and hosted software revenue, collaborative drug-discovery revenue, milestones, and potential royalties from partnered programs.
Schrödinger earns software subscription and hosted software revenue, collaborative drug-discovery revenue, milestones, and potential royalties from partnered programs. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Software pricing is contracted by product module, user count, enterprise scope, hosted deployment, compute consumption, collaboration structure, and research-services commitments. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Schrödinger?
Schrödinger is led by Ramy Farid, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Ramy FaridPresident and Chief Executive OfficerCEO since 2017Leads computational platform and drug-discovery strategy.
- Geoffrey PorgesChief Financial OfficerCFOOwns finance, investor relations, and capital allocation.
- Karen AkinsanyaPresident of R&D, TherapeuticsR&D executiveLeads therapeutic discovery and development strategy.
- Jenny HermanChief Commercial OfficerCommercial leaderLeads software commercialization and customer expansion.
How do you contact Schrödinger's leadership?
Schrödinger publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
IR@schrodinger.com (official published/company IR contact); personal executive format not verifiedHow much funding has Schrödinger raised?
Schrödinger is a public company (Nasdaq: SDGR), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
1990: Founded - Schrödinger begins commercializing computational chemistry software. 2018: Strategic collaborations - Pharma collaborations support platform validation and economics. 2020: IPO - Schrödinger lists on Nasdaq under SDGR. 2025: Full-year results - Schrödinger reports $256M total revenue and $200M software revenue. 2026: Hosted transition - The company continues moving customers toward ratable hosted software licensing.
As of June 2026, Schrödinger's practical funding capacity is best read through Nasdaq: SDGR, $256M 2025 total revenue; $200M 2025 software revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Schrödinger access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Schrödinger get here?
Schrödinger grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 1990Company foundedSchrödinger starts with computational chemistry software.
- 2010sLiveDesign and FEP+ adoptionCollaborative design and free-energy tools become core enterprise products.
- 2020Public listingSchrödinger becomes a public company.
- 2022Therapeutics pipeline advancesInternal and partnered programs expand.
- 2025Software ACV $198MSoftware ACV reaches approximately $198M.
- 2026Hosted software momentumHosted licensing grows as a share of software revenue.
Who are Schrödinger's competitors?
Schrödinger competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- CertaraBiosimulation and model-informed drug-development software peer.
- Simulations PlusDrug-development modeling software competitor.
- Dassault Systemes BIOVIAScientific modeling and informatics software competitor.
- Chemical Computing GroupMolecular operating environment and modeling software competitor.
- OpenEye ScientificMolecular-design software competitor now part of Cadence.
- XtalPiAI and physics-driven drug-discovery technology competitor.
Schrödinger — frequently asked questions
